S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Gas prices dip in NJ, around nation as cold weather returns
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Gas prices dip in NJ, around nation as cold weather returns
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Gas prices dip in NJ, around nation as cold weather returns
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Gas prices dip in NJ, around nation as cold weather returns
NASDAQ:VTVT

vTv Therapeutics - VTVT Stock Forecast, Price & News

$0.93
-0.02 (-2.11%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.93
▼
$0.98
50-Day Range
$0.66
▼
$1.01
52-Week Range
$0.38
▼
$1.40
Volume
50,539 shs
Average Volume
76,788 shs
Market Capitalization
$97.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.50

vTv Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
276.6% Upside
$3.50 Price Target
Short Interest
Bearish
4.14% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.45mentions of vTv Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$17,047 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.27) to ($0.31) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.79 out of 5 stars

Medical Sector

762nd out of 1,028 stocks

Pharmaceutical Preparations Industry

376th out of 501 stocks

See Top Rated MarketRank™ Stocks Here
VTVT stock logo

About vTv Therapeutics (NASDAQ:VTVT) Stock

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and the Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.

Receive VTVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for vTv Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VTVT Stock News Headlines

February 1, 2023 | finance.yahoo.com
Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics
January 31, 2023 | reuters.com
VTVT.PH - | Stock Price & Latest News | Reuters
February 5, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
January 29, 2023 | americanbankingnews.com
vTv Therapeutics (NASDAQ:VTVT) Earns Hold Rating from Analysts at StockNews.com
January 28, 2023 | americanbankingnews.com
vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated by Analysts at StockNews.com
January 20, 2023 | finance.yahoo.com
Private equity firms in vTv Therapeutics Inc. (NASDAQ:VTVT) are its biggest bettors, and their bets paid off as stock gained 21% last week
January 12, 2023 | bizjournals.com
vTv Therapeutics names biotechnology industry veteran Steven Tuch as CFO
January 9, 2023 | finance.yahoo.com
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA
February 5, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
January 5, 2023 | forbes.com
Vtv Therapeutics
December 13, 2022 | finance.yahoo.com
vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer
December 3, 2022 | finance.yahoo.com
Trade Alert: The Independent Director Of vTv Therapeutics Inc. (NASDAQ:VTVT), John Fry, Has Just Spent US$51k Buying A Few More Shares
December 1, 2022 | benzinga.com
vTv Therapeutics Board Member Makes $50K Stock Purchase
November 15, 2022 | finance.yahoo.com
Three months after leadership change, vTv Therapeutics reports cash of $15.3 million and net loss of $4.3 million in Q3
November 11, 2022 | finanznachrichten.de
vTv Therapeutics Inc.: vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update
November 10, 2022 | finance.yahoo.com
vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update
November 10, 2022 | finance.yahoo.com
VTv Therapeutics (VTVT) Reports Q3 Loss, Lags Revenue Estimates
September 23, 2022 | finance.yahoo.com
vTv Therapeutics (NASDAQ:VTVT shareholders incur further losses as stock declines 17% this week, taking five-year losses to 84%
September 22, 2022 | seekingalpha.com
VTVT vTv Therapeutics Inc.
August 19, 2022 | finance.yahoo.com
This Diabetes Drug's 'Licensing Opportunity Is Underappreciated,' Analyst Says
August 19, 2022 | bizjournals.com
After third leadership change in less than a year, vTv Therapeutics Inc. reports $3.2 million net loss in Q2
August 18, 2022 | finance.yahoo.com
After third leadership change in less than a year, vTv Therapeutics Inc. reports $3.2 net loss in Q2
August 16, 2022 | finance.yahoo.com
vTv Therapeutics Announces 2022 Second Quarter Financial Results and Provides Corporate Update
August 13, 2022 | finance.yahoo.com
What You Need To Know About vTv Therapeutics Inc.'s (NASDAQ:VTVT) Investor Composition
August 9, 2022 | finance.yahoo.com
Months after celebrating its first exit, CinRx invests $10M in newest portfolio company
July 27, 2022 | finance.yahoo.com
vTv Therapeutics Announces Paul Sekhri as new President and Chief Executive Officer
July 25, 2022 | finance.yahoo.com
vTv Therapeutics Shares Jump On Equity Investment
See More Headlines
Receive VTVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for vTv Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VTVT Company Calendar

Last Earnings
11/10/2022
Today
2/05/2023
Next Earnings (Estimated)
4/04/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VTVT
CUSIP
N/A
CIK
1641489
Web
www.vtvtherapeutics.com
Phone
(336) 841-0300
Fax
336-841-0310
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.50
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+276.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.30)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-12,990,000.00
Net Margins
-364.61%
Pretax Margin
-1,400.69%
Return on Equity
N/A
Return on Assets
-65.89%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.85
Quick Ratio
3.85

Sales & Book Value

Annual Sales
$4.01 million
Price / Sales
24.24
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.11) per share
Price / Book
-8.45

Miscellaneous

Outstanding Shares
104,580,000
Free Float
103,113,000
Market Cap
$97.20 million
Optionable
Not Optionable
Beta
-1.06

Key Executives

  • Paul Jai Sekhri
    President, Chief Executive Officer & Director
  • Steven Tuch
    Chief Financial Officer
  • Carmen Valcarce
    Chief Scientific Officer & Executive VP
  • Trey M. Lambert
    Senior Vice President & General Counsel
  • Vanessa McDade
    Chief Administration Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













VTVT Stock - Frequently Asked Questions

Should I buy or sell vTv Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VTVT shares.
View VTVT analyst ratings or view top-rated stocks.

What is vTv Therapeutics' stock price forecast for 2023?

2 Wall Street analysts have issued 1 year price objectives for vTv Therapeutics' stock. Their VTVT share price forecasts range from $2.00 to $5.00. On average, they expect the company's share price to reach $3.50 in the next twelve months. This suggests a possible upside of 276.6% from the stock's current price.
View analysts price targets for VTVT or view top-rated stocks among Wall Street analysts.

How have VTVT shares performed in 2023?

vTv Therapeutics' stock was trading at $0.6628 at the beginning of the year. Since then, VTVT stock has increased by 40.2% and is now trading at $0.9294.
View the best growth stocks for 2023 here.

When is vTv Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023.
View our VTVT earnings forecast.

How were vTv Therapeutics' earnings last quarter?

vTv Therapeutics Inc. (NASDAQ:VTVT) released its quarterly earnings data on Thursday, November, 10th. The biotechnology company reported ($0.05) EPS for the quarter, hitting analysts' consensus estimates of ($0.05).

What other stocks do shareholders of vTv Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other vTv Therapeutics investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Onconova Therapeutics (ONTX), Vaxart (VXRT), Agile Therapeutics (AGRX) and Idera Pharmaceuticals (IDRA).

When did vTv Therapeutics IPO?

(VTVT) raised $125 million in an initial public offering (IPO) on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

What is vTv Therapeutics' stock symbol?

vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."

How do I buy shares of vTv Therapeutics?

Shares of VTVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is vTv Therapeutics' stock price today?

One share of VTVT stock can currently be purchased for approximately $0.93.

How much money does vTv Therapeutics make?

vTv Therapeutics (NASDAQ:VTVT) has a market capitalization of $97.19 million and generates $2.02 million in revenue each year. The biotechnology company earns $-12,990,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis.

How can I contact vTv Therapeutics?

vTv Therapeutics' mailing address is 3980 PREMIER DR SUITE 310, HIGH POINT NC, 27265. The official website for the company is www.vtvtherapeutics.com. The biotechnology company can be reached via phone at (336) 841-0300, via email at ir@vtvtherapeutics.com, or via fax at 336-841-0310.

This page (NASDAQ:VTVT) was last updated on 2/5/2023 by MarketBeat.com Staff